LXEO — Lexeo Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $528.44m
- $335.06m
- 53
- 23
- 84
- 53
Annual balance sheet for Lexeo Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Cash and Short Term Investments | 29.4 | 136 | 77.3 | 121 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 29.4 | 137 | 80 | 124 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 0 | 0.174 | 13.8 | 12.3 |
| Other Long Term Assets | ||||
| Total Assets | 29.4 | 137 | 97.1 | 140 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Current Portion of Long Term Debt / Capital Leases | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 0.698 | 7.45 | 14.3 | 17.2 |
| Capital Lease Obligations | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 3.71 | 7.45 | 25 | 26.3 |
| Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Total Equity | 25.7 | 129 | 72.1 | 114 |
| Total Liabilities & Shareholders' Equity | 29.4 | 137 | 97.1 | 140 |
| Total Common Shares Outstanding |